How long does it take for ibrutinib/ibrutinib to take effect?

In some patients, very good partial clinical responses to ibrutinib/Ibrutinib may occur within three to six months. The average duration of ibrutinib therapy in clinical trials was approximately 41 months (range, 2-51 months). Among patients who stopped taking ibrutinib, the average survival after stopping treatment was 8 months.

The recommended starting dose for adults with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and Waldenström's macroglobulinemia (WM) is 420 mg once daily. For chronic graft-versus-host disease, the dosage is based on the age of the patient: adults and children 12 years and older, the dosage is 420 mg once daily; children 1 year to less than 12 years, the dosage is 240 mg/m² PO once daily (maximum 420 mg dose). If toxicity occurs, dose reduction may be necessary. Ibrutinib is typically administered before disease progression or unacceptable toxicity occurs, or, in the case of graft-versus-host disease, before recurrence of the underlying malignancy.

In clinical trials, up to 57% to 69% of people have been reported to have high lymphocyte counts. Of the 77 (57%) patients in Group 1, 95% had symptom resolution within 12 weeks of ibrutinib treatment. This lasted for 12 to 14 weeks, with 94 to 95 percent of patients experiencing symptom relief. Response to treatment and survival without cancer progression were similar between people with high lymphocyte counts during initial treatment and those who did not receive treatment.

Regardless of clinical response, most people remain on ibrutinib indefinitely. This is a common treatment strategy for patients with certain types of leukemia and solid tumors because often when the therapeutic agent is discontinued, symptoms return within a relatively short period of time and the lymph nodes enlarge, especially if the patient has not been taking ibrutinib for a long time or if they have tried many other previous treatments.